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Abstract
Background: This study assessed the gender-specific influence of the cholesteryl ester transfer
protein (TaqIB, I405V) and lipoprotein lipase (S447X) polymorphisms on the response to an oral fat
tolerance test in heterozygotes for familial hypercholesterolaemia.
Methods: We selected and genotyped 80 men and postmenopausal women heterozygous for
familial hypercholesterolaemia (main group) as well as 11 healthy control subjects. Patients were
subgrouped based on their response to oral fat tolerance test. The oral fat tolerance test was
defined as pathological when postprandial triglyceride concentration was higher than the highest
triglyceride concentration observed in healthy subjects (220 mg/dl) at any time (2, 4, 6 or 8 h).
Results: In the pathological subgroup, men had significantly higher incremental area under the
curve after oral fat tolerance test than postmenopausal women. Furthermore, multivariate analysis
revealed a gender association of TaqIB and I405V influence on postprandial lipaemia in this
subgroup.
Conclusion: In conclusion, it seems that gender and TaqIB polymorphism of the cholesteryl ester
transfer protein gene were both associated with the distribution of triglyceride values after oral fat
tolerance test, only in subjects with a pathological response to oral fat tolerance test. Specifically,
men carrying the B2 allele of the TaqIB polymorphism showed a higher postprandial triglyceride
peak and a delayed return to basal values compared with women carrying B2. However, further
investigations in larger populations are required to replicate and confirm these findings.
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Background
The mechanisms that control the cholesteryl ester transfer
protein (CETP) have attracted attention, since plasma
CETP concentration is associated with increased risk for
premature atherosclerosis [1]. The CETP concentration
and activity in plasma is dependent on several factors such
as environmental components including dietary choles-
terol [2], alcohol [3], smoking and obesity [4], gender [5],
and genetic influence (e.g. polymorphism of CETP gene)
[6-8]. CETP plays a major role in the remodeling of lipo-
protein particles by mediating the transfer of high density
lipoprotein (HDL) cholesteryl esters. When the level of
triglyceride (TG)-rich lipoproteins is normal, CETP trans-
fers HDL cholesteryl esters preferentially towards LDL par-
ticles [9]. In contrast, when the levels of fasting [10-12] or
postprandial [11,13] TG-rich lipoproteins are increased,
CETP transfers HDL cholesteryl esters towards larger
VLDL particles resulting in the formation of small dense
LDL particles [9]. Indeed, in type IIB hyperlipidaemia dur-
ing the fasting state, CETP is implicated in the intravascu-
lar formation of atherogenic, small dense LDL through an
indirect mechanism involving an elevated rate of choles-
teryl esters transfer from HDL to VLDL and more specifi-
cally, to large VLDL-1 particles [14]. Moreover, elevated
levels of cholesteryl ester-enriched VLDL-1 are associated
with enhanced formation of atherogenic, small dense LDL
in hypertriglyceridaemic states and notably in hyperlipi-
daemias of phenotypes IIB and IV and in the dyslipidae-
mias of type 2 diabetes and metabolic syndrome [9]. As a
consequence, therapeutic strategies have been developed
to specifically influence the action of CETP [15].
CETP variants have a strong impact on CETP activity and
thus on HDL cholesterol levels [7]. Several polymor-
phisms have been identified in the coding sequence of the
CETP gene including I405V [16]. I405V has been associ-
ated with reduced CETP mass, increased HDL cholesterol
levels and increased cardiovascular risk [6,17]. Another
widely studied CETP polymorphism is TaqIB which may
account for 5.8% of the variance in HDL cholesterol [8].
In normolipidaemic subjects, the absence of the TaqIB
restriction site (B2 allele) is associated with decreased
CETP activity, increased HDL cholesterol levels and
reduced risk of coronary heart disease in males compared
with B1 subjects [18].
Lipoprotein lipase (LPL) also plays a key role in lipopro-
tein metabolism since it hydrolyzes triglycerides from
VLDL and chylomicrons and also removes lipoproteins
from the circulation [19-21]. LPL influences the interac-
tion between atherogenic lipoproteins and the cell surface
as well as the receptors on the vascular wall, playing an
important role in atherogenesis [22-24]. More than 60 dif-
ferent mutations of the LPL gene have been described to
date and they can lead to a reduction in enzyme synthesis
and activity. The S447X is one of the most frequent poly-
morphisms of LPL with an incidence of 17–22% in Cau-
casian populations [25,26]. However, its effect on LPL
activity is controversial. When tested in vitro, this activity
has been described both as increased [27,28] and
decreased [29] but in the majority of studies it was
unchanged [30,31] compared with the wild type protein.
Some studies demonstrated that S447X polymorphism
may be favorable to catabolism of VLDL, decreasing fast-
ing concentrations of triglycerides [26,27,32,33] but it
was not associated with the incidence of coronary artery
disease [34]. The S allele has been associated with higher
triglyceride levels [35], whereas the X allele has been
related with anti-atherogenic lipid profiles and a modest
reduction in coronary disease risk [36].
Patients who are heterozygotes for familial hypercholes-
terolaemia (hFH), and especially men, have more pro-
nounced postprandial hypertriglyceridaemia than
controls [37-40]. Additionally, men have higher fasting
and postprandial TG levels compared with women, which
was demonstrated in a previous study where hFH men
were compared with age-matched premenopausal hFH
women [41]. Furthermore, men develop atherosclerosis
complications 10 to 15 years earlier than women either in
the case of familial hypercholesterolaemia or not. The eti-
ology for these differences could be attributed to gender
specific responses to naturally occurring genetic polymor-
phisms involved in lipid metabolism. Thus, the natural
genetic variation at the CETP and LPL loci could be used
to understand their possible impact on disease. Such
human genetic studies have demonstrated conflicting
conclusions. The TaqI B2 allele has been previously asso-
ciated with protection against an exaggerated postpran-
dial TG rise and a subsequent lowering of the HDL
cholesterol levels in patients with increased TG concentra-
tions (fasting and/or postprandial), by our group [42].
This was attributed to the B2 lowering-effect on CETP
mass and activity which may become more prominent
when TG levels are beyond normal [42].
The aim of the current study was to assess the sex-associ-
ated effect of the TaqIB as well as of two additional poly-
morphisms, the I405V of the CETP gene and the S447X of
the LPL gene, on TG response to fat loading, in clinically
defined hFH. A gender interaction was found with the
TaqIB polymorphism of the CETP gene in patients with a
pathological postprandial triglyceride response.
Methods
Subjects
Eighty hFH unrelated Greek Caucasian subjects (41 men
and 39 postmenopausal women) as well as 11 healthy
control subjects who underwent an oral fat tolerance test
(OFTT) were genotyped. Some patients were previouslyLipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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examined for the impact of the CETP  TaqIB polymor-
phism on postprandial plasma lipoprotein levels [42]. In
the present study, the patients were further examined for
2 polymorphisms (CETP I405V and LPL S447X), includ-
ing CETP TaqIB, however focusing on the gender-specific
influence of these polymorphisms on postprandial lipae-
mia. Eleven healthy subjects (n = 6 men and n = 5 post-
menopausal women) were also recruited and underwent
an OFTT. Controls were normolipidaemic, free of any dis-
ease and had normal maximal treadmill exercise test. All
patients were from the Lipid Clinic of Onassis Cardiac
Surgery Center, Athens, Greece. The center's Institutional
Review Board (IRB) approved the study and subjects gave
their consent for the examination of their DNA. The diag-
nosis of hFH was based on the following clinical criteria:
a) fasting total cholesterol > 290 mg/dl and fasting LDL
cholesterol > 190 mg/dl, b) presence of tendon xantho-
mas in the patient or in a 1st or 2nd degree relative, and,
c) history of premature vascular disease in a 1st degree rel-
ative > 60 years or in 2nd degree relative > 50 years old
[43]. Heavy alcohol drinking, liver and renal disease,
obesity, diabetes mellitus, hypertension, hypothyroidism
and professional sport activity were all criteria of exclu-
sion. None of the patients were on hypolipidaemic treat-
ment.
Table 1: Baseline clinical characteristics of the main group 
(pathological and normal OFTT response)
Pathological
n = 45
Normal
n = 46
p
Age (years) 44.7(23.0) 46.6(24.5) 0.59
BMI (kg/m2) 25.4(4.3) 24.4(3.3) 0.06
Waist (cm) 90.9(14.0) 84.3(17.7) 0.01
TC (mg/dl) 320.3(55.5) 297.2(118.5) 0.10
TG0 (mg/dl) 155.8(87.0) 78.5(31.3) < 0.01
TG2 (mg/dl) 257.3(128.0) 119(43.0) < 0.01
TG4 (mg/dl) 310.9(120.0) 138.8(70.8) < 0.01
TG6 (mg/dl) 291.4(149.0) 130.6(61.3) < 0.01
TG8 (mg/dl) 221.1(147.5) 106.1(54.2) < 0.01
TG AUC (mg/dl/h) 2080.9(853.0) 944.8(342.4) < 0.01
TG i-AUC (mg/dl/h) 846.7(420.1) 351.4(142.4) < 0.01
HDL (mg/dl) 44.2(17.5) 55.7(21.3) < 0.01
LDL (mg/dl) 240.9(51.5) 225.2(111.7) 0.19
Apo A (mg/dl) 141.3(36.3) 156.5(37.4) 0.05
Apo B (mg/dl) 169.3(32.0) 147.8(56.9) < 0.01
Lp (a) (mg/dl) 24.6(19.0) 28.6(27.1) 0.48
Glu (mg/dl) 92.4(15.5) 84.6(13.0) 0.01
Data are presented as medians (interquartile ranges). BMI: body mass 
index, TC: total cholesterol, TG: triglycerides, AUC: area under the 
curve, i-AUC: incremental AUC, HDL: high density lipoprotein 
cholesterol, LDL: low density lipoprotein cholesterol, Apo A: 
apolipoprotein A, Apo B: apolipoprotein B, Lp (a): lipoprotein (a), 
Glu: glucose, hFH: heterozygotes for familial hypercholesterolaemia.
Table 2: Clinical characteristics of the main group (separated in men and women), total cases and controls
Men
n = 41
Women
n = 39
P Total cases
n = 80
Controls
n = 11
p*
Age (years) 33.5(11.5) 55.0(11.0) < 0.01 43.0(24.0) 54.0(31.0) 0.03
BMI (kg/m2) 24.7(3.5) 24.3(4.5) 0.25 24.4(4.0) 25.6(2.0) 0.09
Waist (cm) 93.0(14.0) 78.5(13.0) < 0.01 85.0(17.0) 93.0(26.5) 0.26
TC (mg/dl) 292.0(70.5) 319.0(45.0) 0.01 313.5(56.3) 215.0(39.0) < 0.01
TG0 (mg/dl) 110.0(90.5) 99.0(83.0) 0.53 105.5(85.0) 68.0(33.0) < 0.01
TG2 (mg/dl) 206.0(129.3) 158.0(131.8) 0.20 174.0(119.0) 108.0(53.8) < 0.01
TG4 (mg/dl) 245.0(162.5) 195.0(142.5) 0.12 220.0(160.5) 134.0(52.0) < 0.01
TG6 (mg/dl) 203.0(166.5) 165.0(136.0) 0.40 173.0(171.0) 140.0(63.0) 0.01
TG8 (mg/dl) 157.0(105.0) 134.0(111.0) 0.77 139.5(107.0) 87.0(68.0) 0.02
TG AUC (mg/dl/h) 1568.1(1225.7) 1360.6(809.0) 0.16 1407.9(995.5) 920.8(436.0) < 0.01
TG i-AUC (mg/dl/h) 604.6(630.8) 521.9(420.2) 0.08 564.5(483.8) 346.5(131.7) 0.03
HDL (mg/dl) 40.0(14.5) 55.0(23.0) < 0.01 48.0(18.5) 47.0(12.0) 0.26
LDL (mg/dl) 231.0(61.0) 238.0(45.0) 0.17 232.0(58.8) 135.0(29.0) < 0.01
Apo AI (mg/dl) 132.0(29.3) 158.4(32.0) < 0.01 145.5(40.7) 144.0(31.8) 0.22
Apo B (mg/dl) 153.0(32.5) 162.5(34.1) 0.27 156.9(35.0) 101.0(19.5) < 0.01
Lp (a) (mg/dl) 16.0(15.1) 15.9(30.5) 0.23 16.0(20.3) 21.5(31.4) 0.69
Glu (mg/dl) 86.0(14.3) 90.0(17.0) 0.27 87.5(15.0) 81.5(12.8) 0.03
TaqIB allele frequency n (%)
B1 43 (52.4) 45 (57.7) 0.50 88 (55.0) 7 (35.0) 0.08
B2 39 (47.6) 33 (42.3) 72 (45.0) 13 (65.0)
I405V allele frequency n (%)
I 54 (65.9) 50 (64.1) 0.82 104 (65.0) 16 (72.7) 0.43
V 28 (34.1) 28 (35.9) 56 (35.0) 6 (27.3)
S447X allele frequency n (%)
S 75 (91.5) 69 (88.5) 0.53 144 (90.0) 18 (81.8) 0.26
X 7 (8.5) 9 (11.5) 16 (10.0) 4 (18.2)
Data are presented as medians (interquartile ranges). BMI: body mass index, TC: total cholesterol, TG: triglycerides, AUC: area under the curve, i-
AUC: incremental AUC, HDL: high density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol, Apo A: apolipoprotein A, Apo B: 
apolipoprotein B, Lp (a): lipoprotein (a), Glu: glucose, hFH: heterozygotes for familial hypercholesterolaemia.
*: All comparisons between cases and controls are age-adjusted.Lipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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OFTT protocol
All patients were examined in the outpatient clinic after a
12 h overnight fast. The fatty meal was consumed within
20 min and plasma TG concentrations were measured
before and at 2, 4, 6 and 8 h after the fat load. During this
8 h period, the participants were not allowed to eat or
smoke. They were only allowed to drink water. The con-
tent of the meal has been described elsewhere [44].
Briefly, the fatty meal was a slight modification of that
introduced by Patsch et al. [45], consisting of 83.5% fat,
14.0% carbohydrates and 2.5% proteins and was given in
a dose based on the patient's body surface area (350 g for
2 m2).
There are no official guidelines for the normal ranges of
the OFTT. Therefore, postprandial TG levels were charac-
terised pathological taking into account the current
knowledge from up to date studies. Our OFTT studies on
healthy subjects revealed a limit range of 220 mg/dl [44].
Additionally, several studies of others (reviewed in ref
[46]) have also reported similar results. Consequently, TG
response to OFTT was considered pathological, when any
of the postprandial TG concentration (at 2, 4, 6 or 8 h)
was higher than the highest TG concentration (220 mg/
dl). All hFH patients were grouped according to gender
(main group) and according to the OFTT response (2 sub-
groups).
Determination of blood lipids and glucose
Plasma total cholesterol (TC), TG and HDL cholesterol
were measured using enzymatic colorimetric methods on
a Roche Integra Biochemical analyzer, with commercially
available kits (Roche Diagnostics Gmbh, Mannheim, Ger-
many). The serum LDL cholesterol levels were calculated
using the Friedewald formula in patients with TG levels <
400 mg/dl. Apolipoprotein AI, B and lipoprotein (a) were
measured by nephelometry (Nephelometer BN-100,
Behring, Germany). Blood glucose was measured using
the hexokinase method, with a Dade Behring reagent on a
Dimension (Dade Behring, Liederbach, Germany) instru-
ment. All samples were analyzed within 24 h. The OFTT
protocol has been described elsewhere [44].
Genotyping
The  CETP  (TaqIB, I405V) and LPL  (S447X) polymor-
phisms were detected by using Polymerase Chain Reac-
tion and Restricted Fragment Length Polymorphism
analysis as previously described [3,7,47].
Statistical Analysis
Ad hoc power analysis showed that in order to detect two-
sided differences higher than 20% in the main outcome
variable (TG-AUC) between the two main study groups
(men and women), achieving statistical power equal to
85% at a significance level less than 0.05, we had to recruit
Table 3: Clinical and metabolic characteristics of the hFH-P men and women (subgroup hFH-P).
hFH-P men
n = 24
hFH-P women
n = 21
p
Age (years) 34.0(9.8) 55.0(11.5) < 0.01
BMI (kg/m2) 25.4(4.5) 25.9(4.4) 0.34
Waist (cm) 98.0(13.5) 85.0(15.0) 0.01
TC (mg/dl) 295.0(73.5) 317.0(39.0) 0.07
TG0 (mg/dl) 138.5(89.5) 156.0(78.0) 0.66
TG2 (mg/dl) 244.5(116.0) 240.0(116.0) 0.54
TG4 (mg/dl) 308.5(130.8) 266.0(122.0) 0.12
TG6 (mg/dl) 288.0(95.0) 247.0(208.5) 0.38
TG8 (mg/dl) 202.0(87.0) 206.0(190.0) 0.86
TG AUC (mg/dl/h) 2010.2(635.3) 1665.7(958.6) 0.14
TG i-AUC (mg/dl/h) 934.2(427.1) 707.5(358.1) 0.04
HDL (mg/dl) 37.0(6.8) 55.0(20.0) < 0.01
LDL (mg/dl) 211.5(61.8) 232.0(31.0) 0.23
Apo AI (mg/dl) 127.5(23.1) 162.5(27.1) < 0.01
Apo B (mg/dl) 159.0(31.3) 165.0(47.9) 0.52
Lp (a) (mg/dl) 15.5(15.6) 15.9(30.5) 0.30
Glu (mg/dl) 90.0(10.0) 96.0(21.0) 0.26
TaqIB allele frequency, n (%)
B1 26 (54.2) 25 (59.5) 0.61
B2 22 (45.8) 17 (40.5)
I405V allele frequency, n (%)
I 33 (68.8) 28 (66.7) 0.83
V 15 (31.2) 14 (33.3)
S447X allele frequency, n (%)
S 44 (91.7) 38 (90.5) 0.84
X 4 (8.3) 4 (9.5)
Data are presented as medians (interquartile ranges). BMI: body mass index, TC: total cholesterol, TG: triglycerides, AUC: area under the curve, i-
AUC: incremental AUC, HDL: high density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol, Apo AI: apolipoprotein AI, Apo B: 
apolipoprotein B, Lp (a): lipoprotein (a), Glu: glucose.Lipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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at least 32 individuals for each group. Due to unexpected
conditions, more people entered the study, potentially
increasing its statistical power. Values of numerical char-
acteristics were tested for normality by using the Shapiro-
Wilk test. All variables deviated from normality, thus non-
parametric statistics were used. The Mann Whitney U test
was used for the comparison of numerical values between
2 groups and the Pearson's chi-square test was used for
evaluating any association between categorical variables.
Multiple logistic regression analysis was used in order to
compare various characteristics between cases and con-
trols, adjusting for the effect of age. All continuous varia-
bles are presented as medians and interquartile ranges
(75th – 25th percentile), while categorical variables are pre-
sented as relative frequencies (percentages). Areas under
the curve (AUC) for serial measurements of TG levels at
baseline and after the fatty meal were calculated using the
trapezoid rule. In order to assess the role of alleles on the
TG levels, we performed multiple median (least absolute
value) regression analysis for each study group (Patholog-
ical and normal response to OFTT) adjusting for age, gen-
der and body mass index (BMI), where the TG-AUC was
the dependent variable and the aforementioned parame-
ters were independent variables, since they did not distrib-
ute normally. First and second order interactions between
main effect explanatory variables (response to OFTT, gen-
der and TaqIB allele) were also tested in a suitable multi-
variate model. The t statistic was calculated in order to
assess the significance of each dependent variable in the
models. The level of significance was a priori set at p <
0.05. No adjustment for multiple testing was applied (see
Discussion). Data were analyzed using STATA™ (Version
9.0, Stata Corporation, College Station, TX 77845, USA).
Results
Study groups
Main group
This group consisted of 41 hFH men and 39 hFH women
who underwent an OFTT. All women were postmenopau-
sal in order to exclude hormonal influence on postpran-
dial lipaemia. Women were defined as postmenopausal
when they reported their last menses to have been at least
12 months earlier. They were not on hormone replace-
ment therapy. However, hormone levels were not assessed
to confirm reproductive status.
Table 4: Clinical and metabolic characteristics of the hFH-N men and women (subgroup hFH-N).
hFH-N men
n = 17
hFH-N women
n = 18
p
Age (years) 33.0(13.5) 55.5(13.8) < 0.01
BMI (kg/m2) 24.5(2.9) 22.8(4.1) < 0.01
Waist (cm) 91.0(13.0) 76.0(13.0) < 0.01
TC (mg/dl) 292.0(64.0) 331.0(59.3) 0.08
TG0 (mg/dl) 76.0(30.5) 76.0(38.8) 0.91
TG2 (mg/dl) 128.5(24.8) 112.0(54.5) 0.25
TG4 (mg/dl) 145.5(63.5) 132.0(78.5) 0.21
TG6 (mg/dl) 131.0(60.5) 126.0(64.3) 0.96
TG8 (mg/dl) 103.0(57.5) 99.5(66.8) 0.46
TG AUC (mg/dl/h) 990.3(335.0) 874.0(351.6) 0.37
TG i-AUC (mg/dl/h) 377.3(161.5) 312.8(235.8) 0.17
HDL (mg/dl) 48.0(18.5) 60.0(24.0) 0.02
LDL (mg/dl) 232.0(66.5) 254.5(58.0) 0.26
Apo AI (mg/dl) 137.5(41.7) 158.4(45.8) 0.09
Apo B (mg/dl) 146.8(41.0) 158.5(40.1) 0.26
Lp (a) (mg/dl) 16.0(18.5) 18.4(28.8) 0.65
Glu (mg/dl) 82.0(11.5) 89.0(12.5) 0.35
TaqIB allele frequency, n (%)
B1 17 (50.0) 20 (55.6) 0.64
B2 17 (50.0) 16 (44.4)
I405V allele frequency, n (%)
I 21 (61.8) 22 (61.1) 0.96
V 13 (38.2) 14 (38.9)
S447X allele frequency, n (%)
S 31 (91.2) 31 (86.1) 0.51
X 3 (8.8) 5 (13.9)
Data are presented as medians (interquartile ranges). BMI: body mass index, TC: total cholesterol, TG: triglycerides, AUC: area under the curve, i-
AUC: incremental AUC, HDL: high density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol, Apo A: apolipoprotein AI, Apo B: 
apolipoprotein B, Lp (a): lipoprotein (a), Glu: glucose.Lipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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Lipid values in hFH-P men and women with the B1 or B2 alleles Figure 1
Lipid values in hFH-P men and women with the B1 or B2 alleles. Number of B1 and B2 alleles in men are 26 and 22, 
and in women are 25 and 17, respectively.Lipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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Subgroups
Twenty four out of 41 hFH men [hFH-Pathological (hFH-
P) men] and 21 out of 39 hFH women (hFH-P women)
had a pathological response to the OFTT (subgroup hFH-
P). The remaining 17 hFH men [hFH-Normal (hFH-N)
men] and 18 hFH women (hFH-N women) had a normal
response to the OFTT (subgroup hFH-N).
Controls
This group consisted of 11 healthy subjects with a normal
response to the OFTT.
All participants ingested the individually calculated fatty
meal and tolerated it well.
[1] Baseline clinical, biochemical characteristics and 
postprandial TG levels in hFH-P and hFH-N subgroups
The size of hFH-P and hFH-N groups was 45 and 46 sub-
jects, respectively. The baseline clinical, biochemical char-
acteristics and postprandial TG levels are shown in Table
1. Those participants with a pathological OFTT response
had significantly larger waist perimeter, higher TG levels
in all phases of the study, higher HDL, apolipoprotein B
and glucose baseline levels, while they had significantly
lower apolipoprotein A levels.
[2] Baseline clinical, biochemical characteristics and 
postprandial TG levels in main and both subgroups
The clinical and biochemical characteristics of the main
group and the subgroups hFH-P and hFH-N are shown in
Tables 1, 2, 3, 4. In the main group and subgroup hFH-P,
women were approximately 21 years older and in sub-
group hFH-N, they were 23 years older than men, as
expected by the study design. In the main group and sub-
group hFH-P, women had higher HDL cholesterol and
apolipoprotein AI levels compared with men. In the sub-
group hFH-N, women had lower BMI and higher HDL
cholesterol levels than men. In the main group and both
subgroups, men had higher waist circumference com-
pared with women, though results were within normal
range.
Concerning the OFTT response, no differences were found
between men and women in the main group and in sub-
group hFH-N (Tables 2 and 4, respectively). However, in
the subgroup hFH-P, men had significantly higher TG-
iAUC compared with women (Table 3).
[3] Baseline clinical, biochemical characteristics and 
postprandial TG levels in main group and controls
The clinical and biochemical characteristics of the main
group (total cases) and the controls are presented in Table
2. Patients were about 11 years younger and had signifi-
cantly higher TC, TG, LDL and apolipoprotein B levels
than controls. Patients had significantly higher postpran-
dial TG levels at all hours, higher TG-AUC and TG-iAUC
than controls (Table 2), as expected.
[3] Allelic associations in main group and in both 
subgroups at baseline and postprandially
Patients were not divided based on genotype due to the
small sample size. Regarding the allele frequencies of B1,
B2 (CETP, TaqIB), I, V (CETP, I405V) and S, X (LPL,
S447X), there were no gender differences in the main
group and both subgroups (Tables 2, 3, 4). It should be
also reported that all allele frequencies in hFH with nor-
Gender differences in the response of OFTT in hFH-P  patients with B1 or B2 alleles Figure 2
Gender differences in the response of OFTT in hFH-
P patients with B1 or B2 alleles. TG: triglyceride, TGL: 
triglyceride, HDL: high-density lipoprotein cholesterol, apo 
AI: apolipoprotein AI.Lipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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Lipid values in hFH-P men and women with the I or V alleles Figure 3
Lipid values in hFH-P men and women with the I or V alleles. Number of I and V alleles in men are 33 and 15, and in 
women are 28 and 14, respectively.Lipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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mal response did not differ significantly compared with
those in controls.
There wasn't any association between with B1, B2
(TaqIB), I, V (I405V) and S, X (S447X) carriers and OFTT
response influenced by gender in the main group. Con-
cerning the subgroup hFH-P, women carrying the B2
(TaqIB) allele had higher TC levels (317 ± 36 vs. 295 ± 53
mg/dl, p = 0.05) lower TG levels at the 4th hour (239 ± 65
vs. 279 ± 95 mg/dl, p = 0.03) after fat load, compared with
men with the B2 allele (fig 1 and fig 2). No other differ-
ences between men and women were observed. Women
carrying either the B1 or B2 allele had higher HDL choles-
terol (45 ± 14 vs. 36 ± 10 mg/dl, p < 0.01, 58 ± 12 vs. 39
± 5 mg/dl, p < 0.01) and higher apolipoprotein AI levels
(157 ± 41 vs. 125 ± 27 mg/dl, p < 0.01, 173 ± 27 vs. 130
± 22 mg/dl, p < 0.01) compared with men carrying either
the B1 or B2 allele, respectively (fig 1). Women with the I
(I405V) allele had lower TC levels (315 ± 40 vs. 305 ± 69
mg/dl, p = 0.04) compared with men carrying the I allele
(fig 3). Regarding the rest of lipid parameters, women car-
rying either the I or V allele had higher HDL cholesterol
(56 ± 20 vs. 38 ± 8 mg/dl, p < 0.01, 53 ± 22 vs. 36 ± 7 mg/
dl, p = 0.01), higher apolipoprotein AI (158 ± 26 vs. 130
± 23 mg/dl, p < 0.01, 169 ± 47 vs. 120 ± 23 mg/dl, p =
0.01), and lower incremental TG-AUC (743 ± 363 vs. 934
± 361 mg/dl, p = 0.04, 646 ± 285 vs. 844 ± 427 mg/dl, p
= 0.05), compared with men carrying either the I or V
allele, respectively (fig 3). No association of the S447X
polymorphism with gender and OFTT was found.
Concerning the subgroup hFH-N, women carrying either
the B1 or B2 allele had higher HDL cholesterol levels,
compared with men carrying either the B1 or B2 allele (54
± 23 mg/dl vs. 46 ± 17 mg/dl, p = 0.02, 70 ± 26 mg/dl vs.
50 ± 20 mg/dl, p = 0.01, respectively). No association of
the TaqIB polymorphism with gender and OFTT was
found. Regarding the I405V polymorphism, no difference
was found between genders in I carriers. Compared with
men carrying the V allele, women with the V allele had
higher HDL cholesterol levels (70 ± 22 mg/dl vs. 46 ± 14
mg/dl, p < 0.01). No association of the I405V and S447X
polymorphisms with gender and OFTT was found.
[4] Multivariate analysis
In the total sample, TG response, gender and TaqIB allele
had significant effect on TG – AUC (main effects) (coeffi-
cients = -678.6, 403.4, 678.1, p < 0.01, 0.01, < 0.01 respec-
tively) (Table 5). In addition, the interaction between TG
response and TaqIB allele was also significantly associated
with the dependent variable. This indicates that the differ-
ence in TG-AUC levels between participants with normal
and pathological TG response depends on their allele,
since their interaction term is significantly associated with
the dependent variable.
In the subgroup hFH-P, the presence of the B2 allele was
significantly related to lower levels of TG-AUC (p = 0.01),
adjusting for age (insignificant effect, p = 0.38), gender
(females had significantly lower levels of TG-AUC, p =
0.05) and BMI (slight impact, p = 0.14) (Table 6).
In the subgroup hFH-N, although age and female gender
had a significant relationship with TG-AUC (coefficient =
11.68, -366.25, p = 0.01, p = 0.03, respectively), the B1/B2
allele was not significantly associated with TG-AUC levels
in this group (p = 0.55). BMI did not predict TG-AUC (p
= 0.46) (Table 7). No association of the I405V polymor-
phism with TG-AUC was found in both models.
Discussion
We assessed the gender-specific influence of TaqIB and
I405V polymorphisms of the CETP gene and S447X poly-
morphism of the LPL gene, on postprandial TG levels in
hFH subjects. To decrease the putative sex hormone influ-
ence, men were compared with postmenopausal women.
We found that postmenopausal women seem to lose their
sex-related advantage concerning the OFTT and have sim-
ilar TG response compared with men. Furthermore, in
subjects with a pathological response to OFTT, men carry-
Table 5: Median (least absolute value) multiple regression by total sample based on the response to OFTT.
Explanatory variables Category Coefficient Standard Error P [95% Confidence Interval]
Response to OFTT Pathological vs. normal -678.6 161.8 < 0.01 -998.1 -359.1
Gender Men vs. women 403.4 156.9 0.01 93.6 713.1
TaqIB allele B1 vs B2 678.1 158.3 < 0.01 365.6 990.7
Response to OFTT × gender Pathological & men vs. rest -345.4 218.5 0.12 -776.8 86.1
Response to OFTT × TaqIB allele Pathological & B1 vs. rest -678.1 221.9 < 0.01 -1116.3 -240.0
TaqIB allele × gender B1 & men vs. rest -344.6 213.8 0.11 -766.9 77.8
Response to OFTT × TaqIB allele × 
gender
Pathological & B1 & men vs. rest 378.5 302.4 0.21 -218.8 975.7
Constant 1552.5 118.7 < 0.01 1318.1 1786.9
Triglyceride under the curve (TG-AUC) is the dependent variable.
OFTT: oral fat tolerance test, TG: triglyceride, AUC: area under the curve, BMI: body mass indexLipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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ing the B2 allele of the TaqIB polymorphism showed a
higher postprandial TG peak and a delayed return to basal
values compared with women carrying the B2 allele. In
contrast, there was no gender association between post-
prandial TG levels and the S447X polymorphism of the
LPL gene.
Previous studies concerning hFH subjects and postpran-
dial lipaemia, showed a gender-specific influence on
OFFT [39,40]. Postmenopausal hFH women and hFH
men had a similar TG response to OFTT. Many studies
[48-50], including ours [12,51], have shown that the mag-
nitude of postprandial TG depends on fasting TG levels.
Ageing in women leads to a larger variation in fasting TG
levels, suggesting that with the loss of endogenous estro-
gens, the tight regulation of plasma TG may be lost [52].
Stevenson et al. [53] found a 12% increase of fasting TG
levels after menopause, and others have reported even
higher values [52,53]. Consequently, it seems that the
menopause is associated with reduced protection against
postprandial lipaemia. In the present study, hFH women
and hFH men had similar fasting TG levels (118 ± 55 mg/
dl vs. 125 ± 63 mg/dl, respectively, p = NS), which sug-
gests that these TGs are already increased, since hFH pre-
menopausal women tend to have lower fasting TG
concentrations [53]. Furthermore, there was no gender
difference in allele frequency of both polymorphisms of
the CETP gene in any group. Since both polymorphisms
of the CETP gene were not sex-related, the lack of any
association with gender was expected. The novel finding
of this study is that a significant gender association was
found in TG response to OFTT in hFH-P subjects and the
TaqIB polymorphism of the CETP gene. This suggests that
the modulation of CETP polymorphisms on pathological
postprandial TG levels depends on gender, documented
also by median regression analysis (p < 0.001). This gen-
der difference is probably not mainly related to sex hor-
mones, since the women were postmenopausal. There are
probably other mechanisms beyond sex hormones but
still gender-dependent which can influence TG postpran-
dially. For example, there could be different levels or
localization of CETP expression. The main expression of
CETP takes place in adipose tissue, where the promotion
of selective uptake of HDL occurs [54,55]. Small, lipid
poor adipocytes, in abdominal fat, express higher levels of
CETP messenger RNA and may play major role in men
[56]. Several studies found that higher postprandial TG
levels associate with higher activity and concentration of
CETP [57-60]. Others reported a positive correlation
between the percentage of meal fatty acids and visceral fat
mass [53,61]. However, they could not distinguish
whether there are differences between men and women in
fat uptake from subcutaneous fat. They also observed that
women have more increased adipose tissue blood flow in
the postprandial period than men. A greater blood flow
could deliver more chylomicrons to adipose tissue, poten-
tially increasing the opportunity for additional fat storage
and less exaggeration of hypertriglyceridaemia postpran-
dially. Therefore, blood flow to adipose tissue in the post-
prandial period may regulate regional fatty acid storage.
In contrast, in subjects with normal response to OFTT, no
gender differences were found in postprandial TG levels.
Table 7: Median (least absolute value) multiple regression by group with normal response to OFTT (subgroup hFH-N) based on the 
response to OFTT.
Explanatory variables Coefficient Standard Error p [95% Confidence Interval]
B2 vs B1 -64.7 107.3 0.55 -279.6 150.2
V vs I 135.4 120.0 0.26 -105.1 375.8
Women vs Men -366.3 160.2 0.03 -687.1 -45.4
BMI -20.8 28.2 0.46 -77.2 35.6
Age 11.7 4.5 0.01 2.8 20.6
Constant 1399.8 734.8 0.06 -72.1 2871.7
Triglyceride under the curve (TG-AUC) is the dependent variable.
Table 6: Median (least absolute value) multiple regression by group with pathological response to OFTT (subgroup hFH-P) based on 
the response to OFTT.
Explanatory variables Coefficient Standard Error p [95% Confidence Interval]
B2 vs B1 -473.7 175.6 0.01 -824.0 -123.5
V vs I -4.8 181.6 0.98 -367.0 357.3
Women vs Men -633.9 313.4 0.05 -1259.0 -8.8
BMI 54.0 36.2 0.14 -18.1 126.1
Age 10.3 11.7 0.38 -13.1 33.6
Constant 1855.8 934.8 0.05 -8.5 3720.1
Triglyceride under the curve (TG-AUC) is the dependent variable.Lipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
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Thus, in subjects with a smaller pool of TG-rich lipopro-
teins rapid lipolysis might restrict transfer of cholesteryl
ester out of HDL surface and limit the effect of high CETP
activity linked to the TaqIB polymorphism. This may
explain why subjects in the subgroup with normal
responses to OFTT, who have very low fasting TG (< 100
mg/dl in both genders) show no gender difference in any
of CETP polymorphisms. In all groups, hFH women had
higher HDL cholesterol levels than men with hFH. This
was also reported by others [62].
As already discussed, the TaqI B2 allele has been associ-
ated with protection against an exaggerated postprandial
TG rise and a subsequent lowering of the HDL cholesterol
levels in patients with increased TG concentrations (fast-
ing and/or postprandial) [42]. This was attributed to the
B2 lowering-effect on CETP mass and activity which may
become more prominent when TG levels are beyond nor-
mal [42]. Similarly, restricted CETP activity induced by
the B2 allele also may affect the cholesteryl ester content
of TG-rich lipoproteins (chylomicrons, VLDLs and their
remnants). The lower the CETP activity, the lower the
exchange rate of TGs and cholesteryl esters between lipo-
proteins and the lower the cholesteryl ester content of TG-
rich lipoproteins. Consequently, lower cholesterol returns
to the liver which may result in higher hepatic expression
of LDLR.
A substantial part of our life is spent in the postprandial
state. Several authors have described OFTTs to evaluate
postprandial lipid metabolism. Postprandial hypertriglyc-
eridaemia is not a uniform abnormality. Its pathophysiol-
ogy is not yet defined. Possibly, the response to dietary fat
is a polygenic phenomenon. There is probably a threshold
dietary level that may overwhelm the clearance capacity
and thus alters the postprandial lipid composition of cir-
culating lipoproteins. The more the lipolytic pathway is
saturated in the fasting state, the greater the magnitude of
postprandial triglyceridaemia [46]. The changes in lipo-
proteins observed postprandially mainly involve a
marked increase in TG-rich lipoproteins which promotes
the formation of atheromatic small dense LDLs [46].
Additionally, HDLs are transformed into TG-rich HDL
particles which become a substrate for hepatic lipase and
are cleared more rapidly from the circulation leading to
low serum HDL cholesterol levels [46]. As HDL is the key
mediator of reverse cholesterol transport [63], low HDL
levels may impact this pathway.
From the available data, it is still difficult to establish nor-
mal postprandial TG ranges. In Eriksson's et al. study [64]
the TG levels were 176 ± 17 mg/dl at 3.5 h. Similar results
were found by Boquist et al. [65] (177 mg/dl) and by Eli-
asson et al. [66] (186 mg/dl). Higher TG levels were found
by Weintraub et al. [67] and Cabezas et al. [68], both
approximately 212 mg/dl and by Karpe et al. [69] as
approximately 248 mg/dl. Our OFTT studies on healthy
subjects have revealed a limit range of 220 mg/dl [44],
close to the above values, and this was used as a threshold
TG level in the current study.
This study has limitations. This is an open cross-sectional
study comparing men with postmenopausal women so
the effect of menopause on fasting TG levels was not
assessed. Hormone evaluation was not performed. How-
ever, the classification of women as postmenopausal was
based on the absence of menses for at least 12 months
[70-72], which is widely accepted. No adjustment for
multiple comparisons was applied because every compar-
ison made (for each variable) between genders or allele
carriers leads to independent conclusions, rather than rep-
resenting a whole family of comparisons, where a protec-
tion against the inflation of type I error due to multiplicity
should be used [73]. Additionally, sub grouping led to
small study groups and therefore, a greater number of sub-
jects are needed to draw definite conclusions.
Conclusion
In conclusion, it seems that gender and TaqIB polymor-
phism of the CETP gene were both associated with the dis-
tribution of TG values after OFTT, only in subjects with a
pathological response to OFTT. Specifically, men carrying
the B2 allele of the TaqIB polymorphism showed a higher
postprandial TG peak and a delayed return to basal values
compared with women carrying B2. These patients may
need a more aggressive hypolipidaemic treatment. In con-
trast, no gender differences were found postprandially in
subjects with normal response to OFTT. Furthermore,
there was no influence of the S447X of LPL polymorphism
on gender. In general, in hFH patients with pathological
response to OFTT, the presence of the B2 allele was signif-
icantly related to lower levels of TG-AUC, adjusting for
gender. However, further investigations in larger popula-
tions are required to replicate and confirm these findings.
Competing interests
This commentary paper was written independently; no
company or institution supported it financially. Some of
the authors have attended conferences, given lectures and
participated in advisory boards or trials sponsored by var-
ious pharmaceutical companies.
Authors' contributions
KKA participated in the development of hypothesis, draft-
ing of the manuscript and carried out the genetic analysis.
GDK conceived the study and participated in the develop-
ment of the hypothesis, the study design and drafting of
the manuscript. PMK participated in recruitment of sub-
jects, clinical evaluation and drafting of the manuscript.
CM performed the statistical analysis and interpretationLipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
Page 12 of 14
(page number not for citation purposes)
of data. GH, CM DD participated in the study design and
drafting of the manuscript. DPM participated in revising
the manuscript critically for important intellectual con-
tent. DVC participated in the study design and its coordi-
nation. All authors read and approved the final
manuscript.
References
1. Yamashita S, Hirano K, Sakai N, Matsuzawa Y: Molecular biology
and pathophysiological aspects of plasma cholesteryl ester
transfer protein.  Biochim Biophys Acta 2000, 1529:257-275.
2. Martin LJ, Connelly PW, Nancoo D, Wood N, Zhang ZJ, Maguire G,
Quinet E, Tall AR, Marcel YL, McPherson R: Cholesteryl ester
transfer protein and high density lipoprotein responses to
cholesterol feeding in men: relationship to apolipoprotein E
genotype.  J Lipid Res 1993, 34:437-446.
3. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, Jemaa
R, Evans A, Arveiler D, Marques-Vidal P, Bard JM, Fruchart JC, Duci-
metiere P, Apfelbaum M, Cambien F: Alcohol intake modulates
the effect of a polymorphism of the cholesteryl ester transfer
protein gene on plasma high density lipoprotein and the risk
of myocardial infarction.  J Clin Invest 1995, 96:1664-1671.
4. Freeman DJ, Griffin BA, Holmes AP, Lindsay GM, Gaffney D, Packard
CJ, Shepherd J: Regulation of plasma HDL cholesterol and sub-
fraction distribution by genetic and environmental factors.
Associations between the TaqI B RFLP in the CETP gene
and smoking and obesity.  Arterioscler Thromb 1994, 14:336-344.
5. Kauma H, Savolainen MJ, Heikkilä R, Rantala AO, Lilja M, Reunanen A,
Kesäniemi YS: Sex difference in the regulation of plasma high
density lipoprotein cholesterol by genetic and environmen-
tal factors.  Hum Genet 1996, 97:156-162.
6. Kuivenhoven JA, de Knijff P, Boer JM, Smalheer HA, Botma GJ, Seidell
JC, Kastelein JJ, Pritchard PH: Heterogeneity at the CETP gene
locus. Influence on plasma CETP concentrations and HDL
cholesterol levels.  Arterioscler Thromb Vasc Biol 1997, 17:560-568.
7. Gudnason V, Kakko S, Nicaud V, Savolainen MJ, Kesäniemi YA, Tah-
vanainen E, Humphries S: Cholesteryl ester transfer protein
gene effect on CETP activity and plasma high-density lipo-
protein in European populations. The EARS Group.  Eur J Clin
Invest 1999, 29:116-128.
8. Corella D, Sáiz C, Guillén M, Portolés O, Mulet F, González JI,
Ordovás JM: Association of TaqIB polymorphism in the
cholesteryl ester transfer protein gene with plasma lipid lev-
els in a healthy Spanish population.  Atherosclerosis 2000,
152:367-376.
9. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ:
Atherogenic role of elevated CE transfer from HDL to
VLDL(1) and dense LDL in type 2 diabetes: impact of the
degree of triglyceridemia.  Arterioscler Thromb Vasc Biol 2001,
21:282-288.
10. Lottenberg AM, Nunes VS, Lottenberg SA, Shimabukuro AF, Carrilho
AJ, Malagutti S, Nakandakare ER, McPherson R, Quintão EC: Plasma
cholesteryl ester synthesis, cholesteryl ester transfer protein
concentration and activity in hypercholesterolemic women:
effects of the degree of saturation of dietary fatty acids in the
fasting and postprandial states.  Atherosclerosis 1996,
126:265-275.
11. Contacos C, Barter PJ, Vrga L, Sullivan DR: Cholesteryl ester
transfer in hypercholesterolaemia: fasting and postprandial
studies with and without pravastatin.  Atherosclerosis 1998,
141:87-98.
12. Kolovou GD, Anagnostopoulou KK, Pavlidis AN, Salpea KD, Irak-
lianou SA, Tsarpalis K, Damaskos DS, Manolis A, Cokkinos DV: Post-
prandial lipemia in men with metabolic syndrome,
hypertensives and healthy subjects.  Lipids Health Dis 2005, 4:21.
13. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chap-
man MJ: Cholesteryl ester flux from HDL to VLDL-1 is prefer-
entially enhanced in type IIB hyperlipidemia in the
postprandial state.  J Lipid Res 2002, 43:1652-1660.
14. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ: Action of
atorvastatin in combined hyperlipidemia: preferential
reduction of cholesteryl ester transfer from HDL to VLDL1
particles.  Arterioscler Thromb Vasc Biol 2000, 20:189-197.
15. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG,
Clark RW, Mancuso JP, Rader DJ: Effects of an inhibitor of
cholesteryl ester transfer protein on HDL cholesterol.  N Engl
J Med 2004, 350:1505-1515.
16. Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown ML, Tall AR:
Organization of the human cholesteryl ester transfer pro-
tein gene.  Biochemistry 1990, 2:1372-1376.
17. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tyb-
jaerg-Hansen A: Elevated HDL cholesterol is a risk factor for
ischemic heart disease in white women when caused by a
common mutation in the cholesteryl ester transfer protein
gene.  Circulation 2000, 101:1907-1912.
18. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez
A, Lahoz C, Coltell O, Wilson PW, Schaefer EJ: Association of
cholesteryl ester transfer protein-TaqIB polymorphism with
variations in lipoprotein subclasses and coronary heart dis-
ease risk: the Framingham study.  Arterioscler Thromb Vasc Biol
2000, 20:1323-1329.
19. Pykälistö OJ, Smith PH, Brunzell JD: Determinants of human adi-
pose tissue lipoprotein lipase: effect of diabetes and obesity
on basal- and diet-induced activity.  J Clin Invest 1975,
56:1108-1117.
20. Taylor KG, Holdsworth G, Galton DJ: Clofibrate increases lipo-
protein-lipase activity in adipose tissue of hypertriglyceri-
daemic patients.  Lancet 1977, 8048:1106-1107.
21. Eckel RH: Lipoprotein lipase: a multifunctional enzyme rele-
vant to common metabolic diseases.  N Engl J Med 1989,
320:1060-1067.
22. Beisiegel U, Weber W, Bengtsson-Olivecrona G: Lipoprotein
lipase enhances the binding of chylomicrons to low density
lipoprotein receptor-related protein.  Proc Natl Acad Sci USA
1991, 88:8342-8346.
23. Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, Havekes
LM: Low density lipoprotein receptor internalizes low den-
sity and very low density lipoproteins that are bound to
heparan sulfate proteoglycans via lipoprotein lipase.  J Biol
Chem 1993, 268:9369-9375.
24. Salinelli S, Lo JY, Mims MP, Zsigmond E, Smith LC, Chan L: Struc-
ture-function relationship of lipoprotein lipase-mediated
enhancement of very low density lipoprotein binding and
catabolism by the low density lipoprotein receptor: func-
tional importance of a properly folded surface loop covering
the catalytic center.  J Biol Chem 1996, 271:21906-21913.
25. Jemaa R, Fumeron F, Poirier O, Lecerf L, Evans A, Arveiler D, Luc G,
Cambou JP, Bard JM, Fruchart JC, Apfelbaum A, Cambien F, Tiret L:
Lipoprotein lipase gene polymorphisms: associations with
myocardial infarction and lipoprotein levels, the ECTIM
study. Etude Cas Témoin sur l'Infarctus du Myocarde.  J Lipid
Res 1995, 36:2141-2146.
26. Groenemeijer BE, Hallman MD, Reymer PW, Gagné E, Kuivenhoven
JA, Bruin T, Jansen H, LieI KI, Bruschke AV, Boerwinkle E, Hayden
MR, Kastelein JJ: Genetic variant showing a positive interaction
with beta-blocking agents with a beneficial influence on lipo-
protein lipase activity, HDL cholesterol, and triglyceride lev-
els in coronary artery disease patients. The Ser447-stop
substitution in the lipoprotein lipase gene. REGRESS Study
Group.  Circulation 1997, 95:2628-2635.
27. Henderson HE, Kastelein JJ, Zwinderman AH, Zwinderman AH,
Gagné E, Jukema JW, Reymer PW, Groenemeyer BE, Lie KI, Bruschke
AV, Hayden MR, Jansen H: Lipoprotein lipase activity is
decreased in a large cohort of patients with coronary artery
disease and is associated with changes in lipids and lipopro-
teins.  J Lipid Res 1999, 40:735-743.
28. Kozaki K, Gotoda T, Kawamura M, Shimano H, Yazaki Y, Ouchi Y,
Orimo H, Yamada N: Mutational analysis of human lipoprotein
lipase by carboxy-terminal truncation.  J Lipid Res 1993,
34:1765-1772.
29. Peacock RE, Hamsten A, Nilsson-Ehle P, Humphries SE: Associa-
tions between lipoprotein lipase gene polymorphisms and
plasma correlations of lipids, lipoproteins and lipase activi-
ties in young myocardial infarction survivors and age-
matched healthy individuals from Sweden.  Atherosclerosis 1992,
97:171-185.
30. Sing K, Ballantyne CM, Ferlic L: Lipoprotein lipase gene muta-
tions, plasma lipid levels, progression/regression of coronary
atherosclerosis, response to therapy, and future clinicalLipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
Page 13 of 14
(page number not for citation purposes)
events. Lipoproteins and Coronary Atherosclerosis Study.
Atherosclerosis 1999, 144:435-442.
31. Knudsen P, Murtomäki S, Antikainen M, Ehnholm S, Lahdenperä S,
Ehnholm C, Taskinen MR: The Asn-291->Ser and Ser-477->Stop
mutations of the lipoprotein lipase gene and their signifi-
cance for lipid metabolism in patients with hypertriglyceri-
daemia.  Eur J Clin Invest 1997, 27:928-935.
32. Gagné SE, Larson MG, Pimstone SN, Schaefer EJ, Kastelein JJ, Wilson
PW, Ordovas JM, Hayden MR: A common truncation variant of
lipoprotein lipase (Ser447X) confers protection against cor-
onary heart disease: the Framingham Offspring Study.  Clin
Genet 1999, 55:450-454.
33. Kuivenhoven JA, Groenemeyer BE, Boer JM, Reymer PW, Berghuis R,
Bruin T, Jansen H, Seidell JC, Kastelein JJ: Ser447stop mutation in
lipoprotein lipase is associated with elevated HDL choles-
terol levels in normolipidemic males.  Arterioscler Thromb Vasc
Biol 1997, 17:595-599.
34. Almeida KA, Strunz CM, Maranhao RC, Mansur AP: The S447X pol-
ymorphism of lipoprotein lipase: effect on the incidence of
premature coronary disease and on plasma lipids.  Arq Bras
Cardiol 2007, 88:297-303.
35. Gigek Cde O, Chen ES, Cendoroglo MS, Ramos LR, Araujo LM, Payão
SL, Smith Mde A: Association of lipase lipoprotein polymor-
phisms with myocardial infarction and lipid levels.  Clin Chem
Lab Med 2007, 45:599-604.
36. Wung SF, Kulkarni MV, Pullinger CR, Malloy MJ, Kane JP, Aouizerat
BE: The lipoprotein lipase gene in combined hyperlipidemia:
evidence of a protective allele depletion.  Lipids Health Dis 2006,
5:19.
37. Kolovou GD, Anagnostopoulou KK, Pilatis ND, Giannopoulou M,
Hoursalas IS, Pavlidis AN, Adamopoulou E, Valaora AI, Mikhailidis DP,
Cokkinos DV: The influence of natural menopause on post-
prandial lipemia in heterozygotes for familial hypercholeste-
rolemia.  J Womens Health (Larchmt) 2004, 13(10):1119-1126.
38. Kolovou GD, Anagnostopoulou KK, Pilatis ND, S Iraklianou, Hour-
salas IS, Liberi S, Pavlidis AN, Dritsas A, Mikhailidis DP, Cokkinos DV:
Heterozygote men with familial hypercholesterolaemia may
have an abnormal triglyceride response post-prandially. Evi-
dence for another predictor of vascular risk in familial hyper-
cholesterolaemia Int.  J Clin Pract 2005, 59:311-317.
39. Blackburn P, Lamarche B, Couillard C, Pascot A, Bergeron N,
Prud'homme D, Tremblay A, Bergeron J, Lemieux I, Després JP:
Postprandial hyperlipidemia: another correlate of the
"hypertriglyceridemic waist" phenotype in men.  Atherosclero-
sis 2003, 17:327-336.
40. Kolovou GD, Anagnostopoulou KK, Pavlidis AN, Salpea KD, Irak-
lianou SA, Hoursalas IS, Mikhailidis DP, Cokkinos DV: Metabolic
syndrome and gender differences in postprandial lipaemia.
Eur J Cardiovasc Prev Rehabil 2006, 13:661-664.
41. Kolovou GD, Anagnostopoulou KK, Damaskos DS, Mihas C, Mavro-
geni S, Hatzigeorgiou G, Theodoridis T, Mikhailidis DP, Cokkinos DV:
Gender influence on postprandial lipemia in heterozygotes
for familial hypercholesterolemia.   Ann Clin Lab Sci 2007,
37(4):335-342.
42. Kolovou G, Anagnostopoulou K, Kostakou P, Marvaki C, Mihas C,
Mikhailidis DP, Cokkinos DV: Association between the TaqIB
polymorphism in the cholesteryl ester transfer protein gene
locus and postprandial plasma lipoprotein levels in heterozy-
gotes for familial hypercholesterolemia.  Clin Chem Lab Med
2007, 45:1190-1198.
43. Marks D, Thorogood M, Neil HA, Humphries SE: A review on the
diagnosis, natural history, and treatment of familial hyperc-
holesterolaemia.  Atherosclerosis 2003, 168:1-14.
44. Kolovou GD, Daskalova DC, Iraklianou SA, Adamopoulou EN, Pilatis
ND, Hatzigeorgiou GC, Cokkinos DV: Postprandial lipemia in
hypertension.  J Am Coll Nutr 2003, 22:80-87.
45. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E,
Dunn JK, Gotto AM Jr, Patsch W: Relation of triglyceride metab-
olism and coronary artery disease. Studies in the postpran-
dial state.  Arterioscler Thromb 1992, 12:1336-1345.
46. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis
DP, Cokkinos DV: Clinical relevance of postprandial lipaemia.
Curr Med Chem 2005, 12:1931-1945.
47. Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ: Lipoprotein
lipase gene variation is associated with a paternal history of
premature coronary artery disease and fasting and post-
prandial plasma triglycerides: the European Atherosclerosis
Research Study (EARS).  Arterioscler Thromb Vasc Biol 1998,
18:526-534.
48. Bittner V: Atherogenicity of postprandial lipoproteins and
coronary heart disease.  Endocrinologist 1994, 4:359-372.
49. Ida-Chen YD, Reaven GM: Intestinally-derived lipoproteins:
metabolism and clinical significance.  Diabetes Metab Rev 1991,
7:191-208.
50. Steiner G: Triglyceride-rich lipoproteins and atherosclerosis,
from fast to feast.  Ann Med 1993, 25:431-435.
51. Kolovou GD, Anagnostopoulou KK, Salpea KD, Pilatis ND, Iraklianou
S, Grapsa G, Pantelakis A, Tsarpalis K, Kapnia E, Cokkinos DV: Post-
prandial lipemia in postmenopausal women with high fasting
high-density lipoprotein cholesterol.  Am J Med Sci 2006,
331:10-16.
52. Van Beek AP, de Ruijter-Heijstek FC, Erkelens DW, de Bruin TW:
Menopause is associated with reduced protection from post-
prandial lipemia.  Arterioscler Thromb Vasc Biol 1999, 19:2737-2741.
53. Stevenson JC, Crook D, Godsland IF: Influence of age and meno-
pause on serum lipids and lipoproteins in healthy women.
Atherosclerosis 1993, 98:83-90.
54. Vassiliou G, McPherson R: Role of cholesteryl ester transfer pro-
tein in selective uptake of high density lipoprotein choles-
teryl esters by adipocytes.  J Lipid Res 2004, 45:1683-1693.
55. Benoist F, Lau P, McDonnell M, Doelle H, Milne R, McPherson R:
Cholesteryl ester transfer protein mediates selective uptake
of high density lipoprotein cholesteryl esters by human adi-
pose tissue.  J Biol Chem 1997, 272:23572-23577.
56. Radeau T, Lau P, Robb M, Donnell M, Ailhaud G, McPherson R:
Cholesteryl ester transfer protein (CETP) mRNA abun-
dance in human adipose tissue: relationship to cell size and
membrane cholesterol content.  J Lipid Res 1995, 36:2552-2561.
57. Tall A, Sammett D, Granot E: Mechanisms of enhanced choles-
teryl ester transfer from high density lipoproteins to apoli-
poprotein B-containing lipoproteins during alimentary
lipemia.  J Clin Invest 1986, 77:1163-1172.
58. Fielding CJ, Havel RJ, Todd KM, Yeo KE, Schloetter MC, Weinberg V,
Frost PH: Effects of dietary cholesterol and fat saturation on
plasma lipoproteins in an ethnically diverse population of
healthy young men.  J Clin Invest 1995, 95:611-618.
59. Lottenberg SA, Lottenberg AM, Nunes VS, McPherson R, Quintao
EC: Plasma cholesteryl ester transfer protein concentration,
high-density lipoprotein cholesterol esterification and trans-
fer rates to lighter density lipoproteins in the fasting state
and after a test meal are similar in Type II diabetics and nor-
mal controls.  Atherosclerosis 1996, 127:81-90.
60. Lassel TS, Guerin M, Auboiron S, Chapman MJ, Guy-Grand B: Pref-
erential cholesteryl ester acceptors among triglyceride-rich
lipoproteins during alimentary lipemia in normolipidemic
subjects.  Arterioscler Thromb Vasc Biol 1998, 18:65-74.
61. Romanski SA, Nelson SM, Jensen MD: Meal fatty acid uptake in
adipose tissue: gender effects in nonobese humans.  Am J Phys-
iol Endocrinol Metab 2000, 279:E455-462.
62. Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay A,
Bouchard C, Mauriège P, Després JP: Gender difference in post-
prandial lipemia: importance of visceral adipose tissue accu-
mulation.  Arterioscler Thromb Vasc Biol 1999, 19:2448-2455.
63. Lewis GF: Determinants of plasma HDL concentrations and
reverse cholesterol transport.  Curr Opin Cardiol 2006,
21:345-352.
64. Eriksson JW, Burén J, Svensson M, Olivecrona T, Olivecrona : Post-
prandial regulation of blood lipids and adipose tissue lipopro-
tein lipase in type 2 diabetes patients and healthy control
subjects.  Atherosclerosis 2003, 166:359-367.
65. Boquist S, Ruotolo G, Tang R, Björkegren J, Bond MG, de Faire U,
Karpe F, Hamsten A: Alimentary lipemia, postprandial triglyc-
eride-rich lipoproteins, and common carotid intima-media
thickness in healthy, middle-aged men.  Circulation 1999,
100:723-728.
66. Eliasson B, Mero N, Taskinen MR, Smith : The insulin resistance
syndrome and postprandial lipid intolerance in smokers.
Atherosclerosis 1997, 129:79-88.
67. Weintraub MS, Eisenberg S, Breslow JL: Different patterns of
postprandial lipoprotein metabolism in normal, type IIa,
type III, and type IV hyperlipoproteinemic individuals.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Lipids in Health and Disease 2009, 8:24 http://www.lipidworld.com/content/8/1/24
Page 14 of 14
(page number not for citation purposes)
Effects of treatment with cholestyramine and gemfibrozil.  J
Clin Invest 1987, 79:1110-1119.
68. Cabezas MC, de Bruin TW, Westerveld HE, Meijer E, Erkelens DW:
Delayed chylomicron remnant clearance in subjects with
heterozygous familial hypercholesterolaemia.  J Intern Med
1998, 244:299-307.
69. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A: Post-
prandial lipoproteins and progression of coronary athero-
sclerosis.  Atherosclerosis 1994, 106:83-97.
70. Cooper GS, Baird DD, Darden FR: Measures of menopausal sta-
tus in relation to demographic, reproductive, and behavioral
characteristics in a population-based study of women aged
35–49 years.  Am J Epidemiol 2001, 153:1159-1165.
71. Taylor SM, Kinney AM, Kline JK: Menopausal transition: predict-
ing time to menopause for women 44 years or older from
simple questions on menstrual variability.  Menopause 2004,
11:40-48.
72. Utian WH: Ovarian function, therapy-oriented definition of
menopause and climacteric.  Exp Gerontol 1994, 29:245-251.
73. Kusuoka H, Hoffman JI: Advice on statistical analysis for Circu-
lation Research.  Circ Res 2002, 91:662-671.